Gastrointestinal Endoscopy Excellence Center and Division of Gastroenterology, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
Pancreas Research Unit, Chulalongkorn University, Bangkok, Thailand.
Endoscopy. 2021 Jan;53(1):55-62. doi: 10.1055/a-1195-8197. Epub 2020 Jul 8.
Endoscopic retrograde cholangiopancreatography (ERCP) may not provide complete biliary drainage in patients with Bismuth III/IV malignant hilar biliary obstruction (MHBO). Complete biliary drainage is accomplished by adding percutaneous transhepatic biliary drainage (PTBD). We prospectively compared recurrent biliary obstruction (RBO) rates between combined ERCP and endoscopic ultrasound-guided biliary drainage (EUS-BD) vs. bilateral PTBD.
Patients with MHBO undergoing endoscopic procedures (group A) were compared with those undergoing bilateral PTBD (group B). The primary outcome was the 3-month RBO rate.
36 patients were recruited into groups A (n = 19) and B (n = 17). Rates of technical and clinical success, and complications of group A vs. B were 84.2 % (16/19) vs. 100 % (17/17; 0.23), 78.9 % (15/19) vs. 76.5 % (13/17; > 0.99), and 26.3 % (5/19) vs. 35.3 % (6/17; = 0.56), respectively. Within 3 and 6 months, RBO rates of group A vs. group B were 26.7 % (4/15) vs. 88.2 % (15/17; = 0.001) and 22.2 % (2/9) vs. 100 % (9/9; = 0.002), respectively. At 3 months, median number of biliary reinterventions in group A was significantly lower than in group B (0 [interquartile range] 0-1 vs. 1 [1-2.5]), respectively ( < 0.001). Median time to development of RBO was longer in group A than in group B (92 [56-217] vs. 40 [13.5-57.8] days, respectively; = 0.06).
Combined ERCP and EUS procedures provided significantly lower RBO rates at 3 and 6 months vs. bilateral PTBD, with similar complication rates and no significant mortality difference.
内镜逆行胰胆管造影术(ERCP)可能无法为 Biuth III/IV 型恶性肝门胆管梗阻(MHBO)患者提供完全的胆道引流。完全胆道引流是通过经皮经肝胆道引流术(PTBD)实现的。我们前瞻性比较了 ERCP 联合超声内镜引导下胆道引流术(EUS-BD)与双侧 PTBD 治疗 MHBO 的复发性胆道梗阻(RBO)发生率。
将接受内镜治疗的 MHBO 患者(A 组)与接受双侧 PTBD 治疗的患者(B 组)进行比较。主要结局为 3 个月时 RBO 发生率。
A 组(n=19)和 B 组(n=17)各招募 36 例患者。A 组和 B 组的技术和临床成功率及并发症发生率分别为 84.2%(16/19)比 100%(17/17;0.23)、78.9%(15/19)比 76.5%(13/17;>0.99)和 26.3%(5/19)比 35.3%(6/17;=0.56)。A 组和 B 组在 3 个月和 6 个月时的 RBO 发生率分别为 26.7%(4/15)比 88.2%(15/17;=0.001)和 22.2%(2/9)比 100%(9/9;=0.002)。A 组在 3 个月时的胆道再介入中位数明显低于 B 组(0[四分位距 0-1]比 1[1-2.5];<0.001)。A 组发生 RBO 的中位时间长于 B 组(92[56-217]比 40[13.5-57.8]天;=0.06)。
与双侧 PTBD 相比,ERCP 联合 EUS 治疗在 3 个月和 6 个月时 RBO 发生率显著降低,并发症发生率相似,死亡率无显著差异。